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Literature Review and Synthesis 
Paul Heidenreich and Mark McClellan 
9.1  Introduction 
Age-adjusted mortality rates for ischemic heart disease have fallen for 
the last three decades (Goldman and Cook 1984). The reasons for the de- 
cline-which  include primary prevention of coronary events, secondary 
prevention, improved outcomes of the events themselves, and changes in 
event severity-have  been the subject of considerable debate. Much of the 
debate centers on the relative importance of  medical technology versus 
lifestyle changes or other sources of reductions in risk factors. The debate 
has  important  implications  for  priorities  in  health  care  research  and 
policymaking: If medical interventions have been relatively unimportant, 
then the direction of more resources to research and education on preven- 
tive care may be worthwhile. But resolving the debate is very difficult due 
to the complexity of health care interventions and disease processes. 
Several well-known studies have assessed the contribution of broad cate- 
gories of explanatory factors by synthesizing evidence from clinical trials, 
changes in medical practices, and changes in population risk characteris- 
tics. Risk factor reduction leading to primary and secondary prevention of 
fatal coronary events, including acute myocardial infarction (AMI) and 
ischemia-induced ventricular arrhythmias, appears to have been respon- 
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sible for most of this decline up to the early 1980s. Goldman et al. (1982) 
estimated that changes in lifestyle leading to disease prevention accounted 
for 54 percent  of the decline in ischemic heart disease mortality between 
1968 and 1976. Medical interventions  accounted for 40 percent;  among 
these interventions, 13.5 percent of the decline was attributed to coronary 
care unit treatments, 7.5 percent to treatment of hypertension, 4 percent to 
prehospital resuscitation, 3.5 percent to coronary artery bypass surgery, and 
10 percent  to other medical treatments of  ischemic heart disease (IHD), 
particularly chronic beta-blockade therapy. 
Weinstein  and colleagues  (1  987) have developed the Coronary Heart 
Disease model, a state-transition computer model of  outcome from isch- 
emic heart disease for patients in the United States, to address this ques- 
tion more comprehensively. The first study using the model concluded, like 
Goldman et al., that the bulk of mortality improvement prior to 1980 was 
the result  of lifestyle-related changes in risk factors. However, recent re- 
sults indicated that lifestyle improvements could explain less than 20 per- 
cent of the total  reduction  in heart disease mortality  between  1980 and 
1990. Moreover, primary and secondary prevention through risk factor re- 
duction may be increasingly associated with treatment changes as well, such 
as increased use of lipid-lowering and antihypertensive agents with better 
side-effect and compliance profiles. Thus, medical interventions  seem to 
be growing increasingly important in explaining IHD mortality improve- 
ments. 
Despite the apparent increasing importance of changes in medical tech- 
nology, few  studies have sought to identify  the contributions of specific 
treatment changes. For example, Goldman et al. considered only five ma- 
jor medical interventions in their analysis (and some of these, like coronary 
care unit adoption, actually consisted of a bundle of  new medical treat- 
ments); and the recent Coronary Heart Disease model report (Hunink et 
al.  1997) attributed  approximately half the IHD mortality  reductions  to 
unspecified  “treatment changes.” One reason for this lack of evidence on 
the contributions of particular interventions is the difficulty of separating 
out the contribution of each. Even less evidence exists on the cost implica- 
tions of these different interventions. 
Yet  identifying the contribution of specific treatments to the observed 
improvements in outcomes is important for several reasons. First, it is only 
at the level of specific treatments that the contribution of medical care to 
the overall outcome improvements can be determined explicitly. Second, 
examining specific factors may provide insights about which types of med- 
ical treatments have made the greatest contributions to both outcome im- 
provements  and cost increases. For example,  “high-tech” treatment  use 
has changed in substantially  different ways in different hospitals (Cutler 
and McClellan 1998) and around the world (McClellan et al., in press). Do 
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Moreover, this analysis might identify the most cost-effective  opportunities 
for future changes in heart disease outcomes, and help forecast future im- 
provements in heart disease outcomes. 
In this study, we provide a first step toward synthesizing evidence from 
the clinical literature and a range of empirical databases to try to identify 
the contributions of particular changes in medical treatment in acute myo- 
cardial infarction (AMI) over the last twenty years. Deaths classified as 
due to AM1 make up a relatively small share, perhaps 10 percent, of total 
IHD mortality. Even though its apparent share is small, there are several 
important reasons to study this condition carefully. IHD treatments and 
mortality are closely related to AMI, even though deaths are generally 
classified as caused by AM1 if the death occurs during or soon after the 
AM1 hospitalization.  Many more IHD deaths reflect longer-term conse- 
quences of AMI; for example, arrhythmias resulting from unstable con- 
duction pathways, in turn the result of permanent heart damage from a 
prior AMI. Another reason is that the available clinical trial and medical 
practice evidence on the outcomes of “AM1 episodes” is far more extensive 
than that available for more chronic forms of IHD treated on an outpatient 
basis. Finally, previous studies of long-term outcome trends for AM1 pa- 
tients show that most of the improvement in outcomes for AM1 patients, 
and all of the improvement attributable to hospital care, arises within the 
first week after an AM1 (McClellan and Noguchi 1988;  McClellan and Stai- 
ger 1998). After we  present our detailed analysis of trends in AM1 out- 
comes, we  consider the implications of our results for IHD and other ill- 
nesses. 
In this review, we estimate the reduction in age-adjusted thirty-day mor- 
tality rates for hospitalized AM1 patients, place this improvement in the 
context  of  overall  improvements  in  population  AM1  mortality,  and 
summarize the impact on AM1 mortality trends of the most notable spe- 
cific changes in AM1 treatment, from 1975 to 1995. Thrombolytic therapy, 
primary  angioplasty, aspirin, early beta  blockade,  and ACE-inhibition, 
among other treatments, have been  shown to reduce mortality in AM1 
patients (Lau et al. 1992; ISIS-4 Collaborative Group 1995). How much 
of the reduction in thirty-day mortality rates is explained by  changes in 
medical and surgical therapies during the AM1 episode? What other fac- 
tors are likely to have contributed to the observed improvements? Changes 
in prehospital or posthospital care? Changes in the characteristics of AM1 
patients? We  find that identifiable changes in these factors, especially in 
acute treatment, can explain the bulk  of the observed improvements in 
AM1 mortality for hospitalized patients. Published evidence is insufficient 
to reach exact conclusions on the contributions of these improvements to 
overall IHD mortality trends, and on improvements in the long-term qual- 
ity of life of AM1 survivors. We review qualitative evidence on these issues, 
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have  been among the principal factors responsible for improvements in 
these outcomes as well. 
9.2  Methods 
9.2.1  Trends in Incidence, Treatments, and Thirty-Day Mortality 
We  performed  searches of  the MEDLINE database and reviewed the 
bibliographies of review articles to identify studies describing treatment 
for AMI. We used population-based studies with at least a ten-year range 
whenever possible to determine changes in incidence, thirty-day mortality 
rates, and intervention rates during this period. We reviewed studies de- 
scribing trends in prehospital, in-hospital, and posthospital treatments of 
acute myocardial infarction. Published results from randomized controlled 
trials were used to estimate the probable average benefit from changes in 
these various interventions. These estimates of benefit were considered an 
upper limit for effectiveness, given that the patients enrolled in the trials 
and the trial settings themselves are often not representative of the general 
population. Data were also obtained from large databases of  Medicare 
patients,  including  the  Cooperative Cardiovascular  Project  (CCP) and 
Medicare claims files. 
We obtained estimates of AM1 incidence and case fatality rates (CFRs)' 
from  the National  Hospital  Discharge  Survey (NHDS). NHDS trends 
may not accurately reflect true trends in AM1 case fatality for two reasons. 
First, length of stay increased in the late 1970s, but has decreased some- 
what since the early 1980s. Other things equal, patients remaining in the 
hospital longer are more likely to die in the hospital, so that some of the 
apparent CFR decline may be the result of reduced length of stay. Second, 
transfers have also increased over time, and until recent years (after 1990) 
transfer  AM1 patients were not reliably distinguishable from new  AM1 
patients based on diagnosis codes. Thus, trends in the apparent number 
and mortality of AM1 cases from the NHDS may be misleading. We iden- 
tified AM1 discharges that met the NHDS definition from 1982 onward, 
which includes all patients with primary diagnosis of AM1 or secondary 
diagnoses of AM1 if the reported primary diagnosis was a circulatory dis- 
ease.2 To  improve the comparability  of  results across time periods that 
differed in average length of hospitalization and transfer rates, and thus in 
1. Here we follow the convention of most of the literature and use the term case-futuliiy 
rute to describe the mortality rate during the initial AM1 hospitalization (possibly includ- 
ing transfers). 
2. This coding convention reflects the fact that, even if the non-AM1 circulatory diagnosis 
wils a principal reason for admission to the hospital, it was probably a consequence of the 
AMI.  For  example,  diagnoses of  ischemic  heart  disease complications  or heart  failure 
probably resulted from the accompanying AMI, even if these diagnoses were regarded as the 
principal reason for admission. Trends in Heart Attack Treatment and Outcomes  367 
their apparent CFRs, we  converted case-fatality rates based on all AM1 
admissions to standardized thirty-day mortality rates (MRs) that account 
for trends in transfers and readmissions. That is, we  developed a conver- 
sion factor F(N) based on the average length of stay in the study: 
F(  N)  = [Estimated true MR at 30 days]/[Observed CFR at N days]. 
To  form this conversion factor, we used longitudinal data including trans- 
fers for Medicare patients in 1984 and subsequent years, which provides 
complete information  on mortality at one, seven, and thirty days after 
AM1 (McClellan and Noguchi 1988). Because it fit the data well, we  as- 
sumed a logarithmic relationship between the number of  days following 
AM1 and AM1 CFRs after day one to approximate the relationship be- 
tween the expected thirty-day CFR and a reported CFR for average length 
of stay N.  That is, 
F(  N)  = [MedicareFR at 30 days]/[EstimatedMedicareCFR at N days], 
where estimated Medicare CFR at N days is given by 
[Medicare CFR(  l)] 
+ [In(N - l)/ln(29)][Medicare MR(30) - Medicare MR(l)]. 
Thus standardized thirty-day CFR for a study with average length of stay 
N was calculated as 
Standardized 30-day mortality  = (Reported CFR) x  F(  N) 
Such CFRs were constructed  using NHDS data for  1975, 1980, 1985, 
1990, and 1995. 
9.2.2 
The contribution of each technology to the reduction  in case-fatality 
rate was estimated from the absolute mortality benefit reported for each 
technology (primarily obtained from meta-analyses of published studies), 
accounting for important interactions with other technologies, and from 
the estimated change in use of each technology over time. Because AM1 
treatments have been evaluated separately and at different times, the re- 
ported benefit of the therapies evaluated earlier (beta blockade) may not 
be equal to their benefit when used with therapies that have been applied 
more recently, such as thrombolysis and aspirin. 
To estimate the contribution of each treatment, we  first calculated the 
adjusted odds ratio AOR,(t) for each therapyj in each year t. If the pub- 
lished odds ratio POR,( Y)  from meta-analyses of trials performed around 
year Y was less than 1 (i.e., the therapy was beneficial), then 
AOR,(r) =  1 - [l - POR,(Y)] x  (Interactioneffect),,, 
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where 
(Interaction effect),,  = II{l - [Use,(t) - Useq(Y)] x  Factoq,}, 
and Use,@) is the joint usage of drug i with drug  j in year t,  Use,,(  Y) is the 
joint usage in the (approximate) trial period  I: and Factor,, is the relative 
decrease in effectiveness of drug  j when used with drug i.  In other words, 
we model the impact of changes in other treatments since the treatment of 
interest was studied as a relative reduction in the benefit compared to the 
time of the study; joint effects are generally somewhat less than their indi- 
vidual effects. Where possible, we used published evidence on interactions 
of  treatment effects to guide our assumptions about the magnitudes  of 
the interaction  effect^.^ Where empirical evidence was lacking but clinical 
considerations suggested that interactions were probably nontrivial, we as- 
sumed that the effect of a second treatment on the treatment of interest 
was proportional to the published benefit of the second therapy, using the 
following formula: Factor, = 0.2 X  I 1 -  PORr  I. We conducted a sensitiv- 
ity analysis by  reducing  the assumed interaction to 0. Our “base case” 
interaction assumptions resulted  in noticeable but modest  reductions in 
the effectiveness of individual treatments over time. For example, in our 
analysis, the use of aspirin with beta blockade decreases the effectiveness 
of beta blockade by 5 percent (in relative terms) and the effectiveness of 
aspirin by 2 percent. 
If  the published  odds ratio was greater  than 1.0 and the interaction 
effect was greater than 1, then 
AOR,(Y) = (POR,)/(Interaction effect),, , 
and if  the published odds ratio was greater than 1.0 and the interaction 
effect was less than 1, then 
AOR,(Y)  =  1 - [(l - POR(,,) x  (Interaction effect),,]. 
Evidence on the joint usage of medications over time is also scant; virtu- 
ally all studies report  only univariate  trends in treatment  rates. Conse- 
3. For example, the majority of studies of beta blockade were performed prior to the use 
of thrombolysis. The TIMI-2 trial (McClellan and Staiger 1999), which evaluated beta block- 
ade in conjunction with thrombolysis, found a decrease in recurrent myocardial infarction 
but not in mortality (overall hospital mortality in the substudy was only 2 percent). Similarly, 
nitrate therapy was found to have a positive mortality benefit in studies prior to the use of 
thrombolysis (Van de Werf et al. 1993). In the postthrombolysis era, ISIS-4 (McClellan et 
al., in press) found a minimal benefit which is consistent with a lack of independence between 
the effects of nitrates and more recently used agents (thrombolysis and aspirin). We assumed 
that the absolute benefit for thrombolysis and aspirin was reduced by  2 percent when the 
two drugs were given together based on the ISIS-2 trial. There were no data describing the 
interactions  between other  medications.  We  assumed the  reduction  in  published  benefit 
would be proportional to the published benefit of the added drug. Trends in Heart Attack Treatment and Outcomes  369 
quently, we  also conducted sensitivity analyses on our assumptions about 
the frequency with which drugs are used together. In our base case, we 
assumed that use was independent; that is, Use,,@)  = Use,(t) X Use,@).  For 
sensitivity analysis, we alternatively assumed that use was as correlated as 
possible; that is, Use&) = min[Use,(t), Use,@)]. 
The absolute benefits from interventions were then calculated from the 
AORs for 1975, 1985, and 1995, using the mortality rate from 1975 and 
the AM1 hospitalization rate in the comparison year. For example, we cal- 
culated the absolute change in thirty-day AM1 deaths attributable to treat- 
ment j  as follows. The relative outcome change attributable to the change 
in use of treatmentj  between 1995 and 1975 is given by 
AOR,(95)  x  Usel(95) - AOR,(75)  x  Use,(75). 
Multiplying this relative outcome change (which accounts for changes in 
the use of other treatments) by the standardized thirty-day mortality rate 
for 1975 gives the absolute thirty-day mortality benefit attributable to the 
change in use of the intervention. Multiplying this estimated absolute mor- 
tality benefit times the number of patients hospitalized with AM1 in 1995 
gives the total number of 1995 AM1 deaths averted because of the change 
in treatment. 
9.2.3  Cost-Effectiveness Calculations 
To  estimate the overall cost-effectiveness of all AM1 treatments com- 
bined,  we  determined the total  cost  of care and the expected  quality- 
adjusted  life years gained  for patients  following myocardial  infarction. 
Medicare data were used to determine changes in acute (thirty-day) cost 
of care from 1984 to 1994. All costs were adjusted to 1995 dollars using 
the gross domestic product deflator. Rates of change in acute care costs 
over this period were used to extrapolate costs to 1975 and 1995. We esti- 
mated long term expenditures ($2,000 per year) for survivors of myocar- 
dial infarction based on Medicare data. We estimated the acute survival 
by  using the difference in thirty-day mortality rate from 1975 to 1995 as 
described above. Long-term survival was determined using several differ- 
ent expected survival periods following MI (five years to fifteen years). We 
adjusted years of life gained for quality  of life using the time-trade-off 
utility of 0.88 (Tsevat et al. 1993). All future costs and benefits were dis- 
counted using a rate of 3 percent. We assumed that changes in MI treat- 
ments were responsible for all increases in cost per case, but that they 
provided only a fraction of the total benefit as calculated above. All costs 
were adjusted to 1995 dollars using the GDP deflator. 370  Paul Heidenreich and Mark McClellan 
9.3  Results 
9.3.1 
Trends in AMI Hospitalizations 
The decline in the incidence of new AM1 hospitalizations has been more 
modest. The total number of hospitalized admissions for AMI, as reported 
in the NHDS, actually increased over the 1975-95  time period, especially 
between 1975 and 1985 (table 9.1, line 1). As we  described in section 9.2, 
we  used the ratio of new AMIs to all AM1 discharges from Medicare for 
individuals aged sixty-five to sixty-nine in  1984-94  (table 9.1, line 2) to 
estimate the share of reported AM1 admissions that represented new pa- 
tients, rather than transfers or  readmission^.^ The increase in transfers and 
readmissions  over time  accounts for much  of  the  apparent  increase  in 
AMIs in NHDS, though this adjustment does not completely account for 
an anomalous bulge in AM1 hospitalization  rates in  the early- to mid- 
1980s (table 9.1, line 3). This change may be due in part to idiosyncrasies 
in the reporting of AM1 discharges around the introduction of Medicare’s 
Prospective Payment System in 1983, as well as improved diagnostic tech- 
niques for detecting AM1 (we analyze this hypothesis in more detail be- 
low). To compute AM1 incidence rates over time, we accounted for growth 
in  the at-risk population  aged thirty-five and over (summarized in table 
9.1, line 4). The resulting estimated trend in AM1 incidence, based on the 
population distribution in either 1995 (table 9.1, line 5) or 1975 (table 9.1, 
line 6), suggests that the incidence of new AM1 hospitalizations in the U.S. 
population has declined substantially, from 61 3 per  100,000 population 
aged thirty-five and over in 1975 to 437 per 100,000 in 1995 (1995 popula- 
tion). Because of population aging and population growth, the total num- 
ber of new hospitalizations with true AMIs in the United States has re- 
mained relatively constant, around 540,000 per year, and our benchmark 
analyses are based on this fig~re.~ 
Trends in Mortality  for Hospitalized AMI  Patients 
In  1975 the case fatality rate (CFR) per AM1 admission (not counting 
transfers) according to NHDS was  19 percent (table 9.1, line 7,  and fig. 
9.1).  To  develop a measure more comparable  to the clinical literature, 
which typically considers transfers in case fatality rates, we  adjust for the 
share of admissions not transferred (table 9.1, line 8) and for population 
trends. The result is an estimate of a true, age- and sex-adjusted case fatal- 
Trends in the Incidence and Mortality of AM1 
4. Our results were not sensitive to alternative reasonable assumptions about transfer rates 
and readmission rates within  thirty days, for example by  using a readmission correction 
based on all Medicare beneficiaries rather than sixty-five-to sixty-nine-year-old beneficiaries. 
5. This estimated number of AMIs is smaller than the estimated number of  “coronary 
events” leading to hospitalization that are reported  by  the American  Heart Association; 
these estimates may include many unstable angina patients as well. Table 9.  I  Calculations of CFR, Incidence Including Age Breakdown 
1975  1980  1985  1990  1995  Source 
1, AM1 hospital discharges (thousands, 
2. Fraction due to new patientsh 
unadjusted)” 
577  572  710  652  679  Calculated from NHDS 
0.94  0.91 
521 
0.88  0.83  0.80  Calculated from 
Line 1  X  Line 2 
Medicare 
3. New AM1 hospital discharges 
(thousand unadjusted)’ 
4. Adult US. population age 35+ 
(millions) 
5. New AM1 discharge rate (age/gender 
adjusted to 1995) 
6.  New AM1 discharge rate (age/gender 
adjusted to 1975) 
7. Case fatality rate (%I) (no age/gender 
adjustment) 
8. Fraction of MI admissions not 
transferredb 
9. Case fatality rate (YO)  (adjusted for 
transfers, age/gender adjusted to 1995) 
10. Estimated 30-day fatality rate (“YO) 
(age/gender adjusted to 1995)’ 
11. Total AM1 deaths 
12. Inpatient AM1 deaths in thousands 
13. Estimated deaths in 30 days among 
(no age/gender adjustment) 
hospitalized AM1 patients in 
thousands, no age/gender adjustment 
(‘YO  of all AM1 deaths) 
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158  130  146  117  112  Line 12, adjusted for 
dying within 30 days 
(49)  (44)  (53)  (49) 
,‘Adjusted  for coding changes, discharged alive with length of stay less than three days and age < thirty-five excluded 
hAge  group sixty-five to sixty-nine, data for 1975 and 1980 are extrapolated from the 1985-94  trends. 
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1975  1980  1985  1990  1995 
Fig. 9.1  Change in thirty-day acute MI mortality rate over the last twenty years 
ity rate per new (nontransfer) AM1 admission (table 9.1, line 9). Using the 
extrapolations described above based on Medicare data, this CFR corre- 
sponds to a thirty-day mortality rate of 27 percent (table 9.1, line 10). By 
1995 the admission CFR had declined 12 percent, corresponding to a new- 
case CFR of  14 percent  and a thirty-day  mortality  rate of  17 percent. 
Because length of stay decreased during the last twenty years, the reduc- 
tion in CFR (40 percent) is greater than the reduction in thirty-day mortal- 
ity rate (36 percent). This absolute drop in thirty-day mortality of 9.6 per- 
centage  points  corresponds  to approximately  52,000 more  patients  per 
year surviving to thirty days. Much of our subsequent analysis focuses on 
the factors explaining this substantial mortality trend since 1980. 
Overall (In-Hospital and Out-of-Hospitul) AMI  Incidence and Mortality 
We  were unable to identify any published studies that permitted us to 
quantify long-term trends in the number of out-of-hospital AMIs and of 
AM1 deaths in patients who were not hospitalized for AM1 directly. How- 
ever, using estimates of total AM1 deaths and our results for hospitalized 
AM1 patients, we were able to estimate these trends indirectly. 
The remainder of  table 9.1 places the mortality trend for hospitalized 
AM1 patients in the context of overall AM1 mortality  trends, including 
deaths in patients who do not survive to hospitalization. According to the 
National Death Index, the total number of AM1 deaths among Americans 
thirty-five  and over was approximately  325,000 in  1975 and 218,000 in 
1995 (table 9.1, line 11). To explore the contribution of the mortality de- 
cline among hospitalized  AM1 patients  to this overall mortality  decline, 
we calculated the total deaths among hospitalized patients implied by our 
analysis, which  was based  on data independent  of  the death index.  In 
1975, our estimate of in-hospital case fatalities (before discharge, but pos- 
sibly after transfer) was  1 1 1,000, and the corresponding number for 1995 Trends in Heart Attack Treatment and Outcomes  373 
was 77,000 (table 9.1, line 12). Because death index records should gener- 
ally classify AM1 patients who die acutely (within thirty days) as AM1 
deaths, an increasing number of patients who die after discharge or re- 
admission will be missed using the case-based approach. Consequently, the 
final line of table 9.1 (line 13) reports our estimate of the total number of 
deaths within thirty days after AMI, based on our estimated trends in 
thirty-day  fatalities.  These  deaths  declined  from  158,000 in  1975  to 
112,000 in 1995. 
Because total AM1 deaths consist of prehospital deaths and of deaths 
in  hospitalized  patients,  our findings provide  an  indirect  approach  for 
quantifying trends in prehospital deaths.6  Our estimates of trends in death 
for hospitalized AM1 patients imply that approximately 214,000 AM1 pa- 
tients died before hospitalization in  1975 and 106,000 did so in 1995, and 
that hospitalized AM1 patients accounted for 49 percent of the total AM1 
deaths in  1975 and 52 percent in  1995. These findings on the relative im- 
portance of prehospitalization  and posthospitalization deaths are consis- 
tent with estimates from earlier years (Goldman et al. 1982) that 50 to 60 
percent of acute MI deaths occurred outside the hospital. 
They are also consistent with previously published studies on the decline 
in  out-of-hospital deaths from ischemic heart disease. Because of these 
difficulties in  quantifying  out-of-hospital AM1 deaths separately,’ most 
published studies consider trends in out-of-hospital IHD deaths generally, 
including deaths from cardiac arrest as well as AMI. The number of such 
deaths has declined impressively over the last twenty years. The incidence 
of out-of-hospital IHD deaths in the Minneapolis area was approximately 
150 per  100,000 in  1990, a reduction of more than 50 percent compared 
to the 1970 rate of  330 per 100,000 (McGovern et al. 1996; Gillum et al. 
1983). This  community  study  concludes  that  the  reduction  in  out-of- 
hospital deaths, which include a substantial number of AM1 deaths, ac- 
counts for the bulk of the observed improvements in overall IHD mortality 
rates. Our results imply a similar conclusion for AMI: The improvements 
in mortality  for hospitalized AM1 patients, impressive as they were, ac- 
counted for only around 30 percentX  of the total decline in AM1 deaths 
between  1975 and 1995-though  they were relatively more important in 
6. Note that this cannot be done directly from death records, even though they report 
whether a death occurred in or out of the hospital. The out-of-hospital group includes those 
dying of AM1 prior to hospitalization, as well as the increasing number of patients dying 
after their initial hospitalization. 
7. We emphasize that it is difficult to quantify reliably the number of deaths from AM1 
without  hospitalization. Especially if  autopsy of  an individual  “found down” is  not per- 
formed, it may be difficult to determine whether patients with IHD died from a new AM1 
or from a ventricular arrhythmia. As a result, most out-of-hospital deaths in the setting of 
IHD are classified  with a  nonspecific IHD diagnosis (McClellan and Staiger 1999). One 
reason that reported AM1 mortality rates are so low relative to IHD mortality rates is that 
such nonspecific out-of-hospital deaths are relatively common. 
8. Total deaths among hospitalized  patients declined by  46,000, while total prehospital 
deaths declined by  108,000. 374  Paul Heidenreich and Mark McClellan 
1985-95  than in the previous decade. Part of this decline resulted from an 
increasing share of AM1 patients being hospitalized-according  to our es- 
timates, 72 percent in  1975 compared to 84 percent in 1995. But this in- 
creasing rate of hospitalization  accounts for only a small fraction of the 
more than 100 percent decline in prehospital deaths. 
Our estimates imply a decline in the number of AM1 events resulting in 
either  prehospital  deaths  or  hospitalization  from  757,000  in  1975  to 
646,000 in 1995. With the growth and aging of the population during this 
period, this trend implies a decline in  the rate of  serious AM1 events of 
more than 40 percent over the twenty-year period. The true decline in both 
the rate and number of serious AM1 events may be even larger. Trends in 
the number of individuals who have a mild AM1 but do not seek treatment 
cannot be estimated from any reported health statistics. With public edu- 
cation campaigns about  the  importance of  responding  to classic AM1 
symptoms, it is possible that patients are increasingly seeking out medical 
care, but the magnitude of this trend toward patient-initiated hospitaliza- 
tion for AM1 is unclear. More clear, as we  describe below, is the effect of 
changes in technology for diagnosing AM1 on the detection, and probably 
the hospitalization,  of patients with mild AMIs. In any case, as we  turn 
to our detailed analysis of changes in treatment and outcomes given the 
occurrence of AMI, it is worth noting that a decline in the rate of serious 
AM1 events was the most important contributing factor to the reduction 
in AM1 mortality over the past twenty years. 
9.3.2  Mortality Consequences of Changes 
in Acute In-Hospital Treatment 
Thrombolysis 
By  1995 thrombolytic use was 31 percent, according to data from the 
National Registry of Myocardial Infarction (NRMI) (Rogers et al. 1996) 
(table 9.2). The use of thrombolytic therapy in 1975 was effectively 0 per- 
cent. After adjustment for concomitant use of other drugs, we  estimated 
that the absolute mortality reduction due to thrombolytics in 1995 was 4.6 
percent. This would explain 16 percent of the reduction in the AM1 thirty- 
day mortality rate from 1975 to 1995. 
Time from symptom onset to treatment is a major determinant of suc- 
cessful thrombolysis. If thrombolysis can be initiated within one hour then 
the relative risk reduction is near 50 percent, which would lead to an abso- 
lute mortality reduction of as much as 9.5 percent. If we  assume that in 
1995 such rapid treatment was actually achieved, then thrombolysis could 
explain 35 percent of the overall reduction in thirty-day mortality. How- 
ever, this estimate is likely to be much too high. Data from Worcester in 
1985 (median time to hospitalization 2.0 hours) (Yarzebski et al. 1994a), 
NRMI (2.8 hours to treatment in 1990 and 2.7 hours in 1993) (Rogers et Table 9.2  Use of Interventions for Acute Myocardial Infarction 
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al. 1994), and GUSTO (median time to treatment 2.7 hours) (GUSTO 111 
Investigators 1997) suggest that there has been little improvement in time 
from symptom onset to thrombolysis up to 1995. Largely anecdotal results 
since 1995 suggest that time to thrombolytics may be declining, perhaps 
accounting for very recent mortality improvements. 
Beta Blockade 
In 1985 and 1990, beta blockade use was stable at 47 to 48 percent of 
MI cases (table 9.2). Data from Minnesota in  1992-93  indicate a slight 
increase to 53 percent use. This is more than double the 1975 value of 21 
percent. The published odds ratio demonstrating a survival benefit with 
beta blockade is 0.88. However, the majority of data regarding the benefit 
of beta blockade was collected prior to the use of thrombolysis and pri- 
mary pecutaneous transluminal coronary angioplasty (PTCA). Thus, the 
benefit may not be as great in conjunction with other current treatments 
(Becker 1994; Van de Werf et al. 1993). After adjustment for interactions 
with other therapies, we  estimate that increased use of beta blockers ac- 
counts for an absolute mortality reduction of 2.0 percent, or 6 percent of 
the reduction in the thirty-day mortality rate. 
Aspirin 
Aspirin use in  1995 was estimated to be 75 percent, in contrast to 15 
percent use in  1975 (table 9.2). If we  assume that the absolute survival 
benefit from aspirin after adjustment for use of thrombolysis is 4.0 percent 
(ISIS-2 Collaborative Group 1988), then aspirin use would explain 28 per- 
cent of the reduction in thirty-day mortality rates. These results suggest 
that the increase in aspirin use had a far greater impact on the acute MI 
thirty-day mortality rate than thrombolysis or beta blockade. A major rea- 
son for aspirin’s estimated importance is the magnitude of its increase in 
use, perhaps because of less physician concern about complications com- 
pared to thrombolytics or beta blockers. 
Culcium Channel Blockers 
It is unclear whether calcium channel blockers provide any benefit in 
AMI. Meta-analyses by  Lau et al. (1992) and Teo, Yusuf, and Furberg 
(1993) have demonstrated a harmful nonsignificant trend with the use of 
these drugs (table 9.3). We assumed that 1995 use was similar to 1993 use 
of 31 percent based on data from NRMI (Rogers et al. 1994)-it  may in 
fact be somewhat lower. Use in 1975 was zero, as these drugs had not yet 
been developed. Based on Lau et al.3 summary odds ratios, greater cal- 
cium channel antagonist use would account for a 7 percent absolute in- 
crease in mortality, leading to 4,700 more deaths (assuming 540,000 myo- 
cardial  infarctions  in  1995). However, newer calcium channel blockers 
have not been evaluated in these meta-analyses. Their effect on AM1 mor- 
tality is unclear, and possibly favorable. Table 9.3  Effects of Interventions for Acute Myocardial Infarction 
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0.75  0.78 
0.92  0.94 
0.78  0.83 
1.13  1.10 
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0.92  0.94 
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Hennekens et al. (1996) 
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dCalculated  assuming an odds ratio of 0.75 for thrombolytics and an odds ratio with benefit of PTCA vs. thrombolysis of 0.66. 
bAbsolute benefit assumed equal to nitrate therapy and ACE inhibition. Upper absolute benefit estimate assumed equal to thrombolysis. Lower absolute 
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Nitrates 
It is also unclear if nitrates still provide any survival benefit in acute MI. 
A  meta-analysis  reported  with the results from ISIS-4 demonstrated  a 
small  survival  benefit  with  oral  nitrates  (ISIS-4  Collaborative  Group 
199.5). A metanalysis of IV nitroglycerin in acute MI in the prethrombo- 
lytic era found a more substantial mortality reduction of 20 percent (Yusuf 
et al. 1988). An explanation for these seemingly contradictory findings is 
that the nitrate effect is not independent of the effect of thrombolysis and 
aspirin. Another possible explanation is that the intravenous route is more 
beneficial than the oral route. We used the more conservative ISIS-4 value 
for our analysis (odds ratio 0.94), which reflected interaction effects with 
other treatments that were less prominent in  earlier years. Because the 
increase in use of more potent therapies that interacted with nitrate effects 
was large, the incremental contribution of nitrates to AM1 survival in 1995 
was slightly less than in 1975. 
Heparin 
In studies performed before widespread use of thrombolytics, heparin 
and other anticoagulants have been shown to reduce mortality (summary 
odds ratio 0.78, equivalent to a 3.9 percent  absolute benefit with  1975 
overall mortality) (Lau et al. 1992). In 1993 NRMI, 70 percent of patients 
receive heparin. Because heparin is now often considered part of “throm- 
bolytic  therapy”  we  assumed  that  all  patients  receiving thrombolytics 
would receive heparin and that heparin provided no substantial additional 
benefit in these patients. Of the 69 percent that did not receive thrombolyt- 
ics in  1995, 57 percent were estimated to have received heparin, that is, 
(69 -  31)/(100 -  31). No data were available on heparin use in 1975; data 
from 1985 (Minnesota) showed that 53 percent of patients received hepa- 
rin  (McGovern et al.  1996). Summary data from the Worcester cohort 
from 1975 through 1988 found that 65 percent of patients received antico- 
agulants (Goldberg et al. 1991), suggesting that heparin use did not in- 
crease markedly from  1975 to  198.5. If the increase in use over the last 
twenty years was only 4 percent (53 percent to 57 percent) then less than 
1 percent of the improvement in MI thirty-day mortality rates is explained 
by  heparin use. However, if heparin use was in fact much lower in 1975, 
then it would explain more of the mortality improvement: If 1975 use were 
20 percent, then the increased use would explain 15 percent of the 1975-95 
mortality reduction. 
Lidocaine 
It is  now  known  that  prophylactic  lidocaine is not  beneficial and  is 
probably harmful in the setting of AM1 (Teo, Yusuf, and Furberg 1993). 
Lidocaine use was 31 percent in  1975 (Goldberg et al. 1987b), increased 
in the early 1980s, and subsequently dropped to 16.2 percent in  1995 ac- Trends in Heart Attack Treatment and Outcomes  379 
cording to NRMI (Chandra et al. 1996). Data from Minnesota (which did 
not include patients of age seventy-five years or older) suggested an even 
greater use of lidocaine (43 percent in 1970 and 67 percent in 1979) (Mc- 
Govern, Folsom, et al. 1992). If we  assume that nonprophylactic, poten- 
tially beneficial use remained constant from 1975 to 1995, then the abso- 
lute decrease in prophylactic use is approximately  15 percent (31 - 16, 
according to Worcester data). Meta-analyses have suggested that the lido- 
caine increases mortality by an absolute 6 percent, assuming a 22.6 per- 
cent overall mortality (Teo, Yusuf, and Furberg 1993). Thus the substantial 
decline in  the use of prophylactic  lidocaine  since  1975 would  have ex- 
plained  11 percent of the reduction in thirty-day mortality rates. 
Magnesium 
Early studies of intravenous magnesium suggested an absolute survival 
benefit for patients with AM1 (Teo et al. 1991). However, a large recent 
trial  (ISIS-4 Collaborative  Group  1995) found  no benefit  and  a  slight 
harmful trend. Because there is no evidence that the recent finding reflects 
an interaction  of newer  therapies  with  the magnesium  benefit,  we  used 
the estimated effect from ISIS-4. Magnesium use was 8.5 percent in 1995 
according to NRMI data, and we  assumed  it to be 0 percent  in  1975. 
Thus in any case, because so little magnesium is used, the effect on overall 
mortality is very small (<1 percent). If an absolute harm of 0.3 percent is 
assumed, then  magnesium  use would  have led  180 extra  deaths within 
thirty days following MI in 1995. 
Primary PTCA 
Primary PTCA use in  1995 was estimated to be  10 percent based  on 
data from NRMI (Rogers et al. 1996) and 0 percent in 1975. Using a 3.8 
percent absolute benefit of primary PTCA (assumed equal to thrombolysis 
[Every et al. 19961, table 9.3) the increased use would explain 4.6 percent 
of the reduction in thirty-day mortality rates. A meta-analysis by Weaver 
et al. (1997) suggests that PTCA has an absolute survival  benefit  over 
thrombolysis. If this is true (absolute benefit 9.9 percent) then 9.8 percent 
of the reduction in the acute MI mortality rate is attributable to primary 
PTCA. 
Immediute or  Urgent Coronary Artery Bypuss Graft (CABG) 
One small randomized trial suggested no benefit to urgent CABG versus 
waiting (Koshal et al. 1988). Data from NRMI suggest that use of CABG 
during acute MI has not increased markedly (5.7 percent  in  1995) com- 
pared to an estimate of 2.3 percent for 1975 (average based on Minnesota 
data from  1970 and McGovern  et  al.  1996; McGovern,  Folsom,  et al. 
1992). If we  assume that urgent CABG has a modest net absolute benefit 
(1 percent) in the additional patients who received it, then the increased 
use of CABG would explain 0.6 percent of observed decline in the thirty- 380  Paul Heidenreich and Mark McClellan 
day mortality rate. Even if we assume a comparable benefit to early PTCA, 
the small increase in CABG use explains only a small share of the mortal- 
ity improvement. 
Acute Revascularization 
Use of catheterization  and revascularization,  particularly angioplasty, 
within thirty days of AM1 has increased markedly in use since 1975. The 
mortality benefits of these changes in treatment are not clear. Several re- 
cent  studies have documented  no survival  benefit  (and possible harm) 
from routine catheterization and revascularization soon after AM1 in cases 
without recurrent chest pain or other ischemic symptoms (Boden et al. 
1998). Thus, for most AM1 patients, thirty-day mortality benefits of early 
revascularization  are probably zero. However, a subset of AM1 patients 
who experience recurrent ischemic symptoms soon after infarct are gener- 
ally viewed as appropriate candidates for revascularization  (Ryan et al. 
1996). Unfortunately, no trial results are available regarding urgent revas- 
cularization for patients presenting with MI. Both PTCA and CABG may 
have longer-term mortality benefits that are greater than their acute bene- 
fits; we return to this issue below. 
Few patients hospitalized  for AM1 underwent  CABG or angioplasty 
within thirty days in 1975. According to Medicare data, 5.8 percent under- 
went revascularization in 1985; assuming that the relative odds of proce- 
dure use were constant, this corresponds to a rate of 7.3  percent of nonel- 
derly patients. In 1994 the elderly rate was 14.8 percent, compared with 
18.6 percent among the nonelderly in California. If we assume an average 
absolute thirty-day mortality benefit of 1 to 2 percent in these patients- 
which probably consists of a more substantial benefit for a small share 
of  patients, and little benefit for others-then  increased revascularization 
explains 0.6 to 1.2 percent of the reduction in acute mortality. 
Pulmonary Artery Catheterization 
Use of pulmonary artery catheterization increased from 1975 to  1984, 
then  declined  thereafter  among all patients with AM1 studied. Among 
high-risk patients with AM1 complicated by heart failure or hypotension, 
use  of pulmonary  artery  catheterization  increased until  1988, then  de- 
clined in use from 1990. For the combined study periods, 14.7 percent of 
all patients with AM1 studied and 25.4 percent of those with complicated 
AM1 underwent pulmonary artery catheterization (Yarzebski et al. 1994b; 
Gore et al. 1987). To date there is no evidence that pulmonary artery cathe- 
terization improves mortality in patients with myocardial infarction (Zion 
et al. 1990). In fact, there is concern that these procedures may increase 
mortality, possibly by causing infection or by direct cardiac injury (Con- 
nors et al. 1996; Dalen and Bone 1996). For our analysis, we assumed no 
mortality effect from pulmonary artery Catheterization. Trends in Heart Attack Treatment and Outcomes  381 
Coronary Care Units 
The diffusion of coronary care units was largely complete by the late 
1970s. Although we cannot rule out a subsequent mortality benefit from 
improvements  in arrhythmia  detection and complex AM1 management, 
other changes in CCU technology are unlikely to have made a substantial 
contribution in themselves to the drop in thirty-day mortality rates from 
1975 to 1995. We discuss the harder-to-measure benefits of increasing skill 
and experience in CCU and other decisions below. 
Overall Efect of’  Changes in Acute Inpatient  Treatments 
The contribution of each of these treatments to the overall reduction in 
mortality rates during the last twenty years is summarized in table 9.4 and 
figure 9.2. This analysis compares benefit and use in 1995 with benefit and 
use in 1975. An alternative analysis is displayed in table 9.5, which exam- 
ines the impact of increasing treatment use from 1975 to 1995 levels hold- 
ing all other drug use constant  at  1995 levels. Table 9.4 shows that in- 
creased use of beta blockers, aspirin, thrombolysis, primary PTCA, and 
ACE inhibitors can explain 62 percent of the reduction in thirty-day mor- 
tality from  1975 to  1995. Including the treatment changes in lidocaine, 
calcium channel blockers, nitrates, magnesium, and revascularization in- 
creases the share of the reduction  explained  to 60 percent,  or approxi- 
mately 6 percentage points lower mortality. 
Our findings are mildly sensitive to the assumed joint effects and uses 
of therapies. If no interaction between therapies is assumed, then 79 per- 
cent of the reduction would be explained. Our base-case analysis also as- 
sumes that therapies  are used independently. If we  instead  assume that 
drugs are always given together (patients receive many therapies, or almost 
no therapies), then the consequences  of interactions  between treatments 
will  be  larger.  If  this  assumption  is true,  then  the five major  therapies 
would explain only 59 percent of the decline in mortality, and all of the 
therapies would explain about 56 percent. 
To explore whether the treatments we identified made different contribu- 
tions over different time periods, we examined the time periods from 1975 
to 1985 and 1985 to 1995 separately (table 9.4). From  1975 to 1985, in- 
creased  use of the five major MI therapies explained 42 percent  of the 
reduction in mortality during this period. The moderate increase in thera- 
pies mirrored the moderate drop in mortality during this decade. Increased 
use of  beta blockers accounted for 20 percent  of the drop in mortality, 
followed by  thrombolysis  (1 6 percent)  and aspirin  (6 percent).  Nitrate 
therapy  may have had a greater  impact on mortality during this period 
when little thrombolysis or aspirin were used. If the survival benefit for 
nitrate therapy is as estimated by Yusuf et al. (1988) (odds ratio 0.79 for 
oral nitrates), then the increased use of nitrates from 1975 to 1985 would Table 9.4  Calculation of Benefit from Acute Myocardial Infarction Therapies 
Reduction in Mortality Explained~’  (“A>) 
Odds Ratio  Increase in  Major  Major  Major  All  All Therapies, 
Use (%),  Therapies,  Therapies,  Therapies,  Therapies,  No Interaction, 
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Fig. 9.2  Contribution of the change in usage of individual therapies to the 
reduction in case-fatality rate from 1975 to 1995 
Note: The total percent explained is 61 percent. This analysis assumes that point estimates 
of effect size from the meta-analysis are correct. The contribution of lidocaine was due to a 
reduction in use. 
Table 9.5  Reduction in Mortality Explained Due to Increasing Drug Use from 
1975 to 1995 Levels (YO) 
Direct  Indirect Effect  Total 















































Nore: Percent of  1995-75  decrease in acute MI thirty-day mortality rates explained by  in- 
creasing an individual drug usage from 1975 to 1995 levels. All other drugs are assumed to 
be used at 1995 levels. Indirect effects are opposite to direct effects because of negative inter- 
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have explained a much larger share (22 percent) of the decline in thirty- 
day mortality rate during this period. 
From 1985 to 1995, a more substantial drop in thirty-day mortality oc- 
curred compared to the 1975-85  period (approximately 6.7 versus 3.7 per- 
centage points, table 9.1). This greater improvement was associated with 
a large increase in the use of the major therapies shown to be effective in 
AM1 care (tables 9.1 and 9.2). The relative contribution of different treat- 
ments to the drop in mortality also changed substantially. Beta blockers, 
the use of which increased only modestly during this time period, were un- 
important. Aspirin explained 33 percent of the decline, the increased use 
of thrombolysis explained  15 percent, primary PTCA explained 13 per- 
cent, and ACE inhibition explained 4 percent. 
In contrast to our base case, if we  assume the average harm from cal- 
cium channel blockade is as reported in the meta-analyses, then the impact 
of changes in interventions on the overall mortality rate during these two 
time periods differs markedly. Because there was a large increase in cal- 
cium blockade from  1975 to  1985, the benefit from proven therapies  is 
largely offset by the harm from rapid diffusion of calcium channel block- 
er~.~  Conversely, because calcium channel blockers (and to a lesser extent 
lidocaine) were used less frequently by  1995, the overall contribution of 
effective treatments to the reduction  in mortality from  1985 to 1995 in- 
creases to 84 percent. We find these average effects for potentially harmful 
treatments to be implausible. In any case, all of our estimates suggest that 
medical treatments for acute MI were much more important in reducing 
AM1 mortality during the ten years following 1985 compared to the prior 
ten years. 
The major changes in  inpatient AM1 treatment we  evaluated do not 
include all of the changes in the acute hospital management of AM1 that 
have occurred in the past two decades. Other treatment changes that may 
have contributed to the reduction in AM1 mortality include improved sup- 
portive care for heart failure and shock, improved arrhythmia monitoring 
and defibrillation, stenting and other treatments to improve vessel patency 
after angioplasty, and miscellaneous other therapies. The importance of 
these additional changes in the mortality trends is unclear, because of the 
absence of published information  on effects from randomized controlled 
trials or other studies on effectiveness,  and on trends in treatment use over 
time. Even though none of these treatments are used on a large share of 
AM1 patients, they may nonetheless account for part of the residual unex- 
plained mortality trends. However, the following sections describe expla- 
nations for the remaining mortality improvement other than these addi- 
tional changes in hospital care. 
9. Lidocaine also accounts for a less substantial adverse change in outcomes from 1975 to 
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Changes in Appropriateness of Care 
In the preceding subsections, we  have focused on changes in treatment 
rates in AM1 patients. Even if treatment rates and AM1 patient character- 
istics remain unchanged, outcomes may nonetheless improve if treatments 
are allocated to patients more effectively.  Treatment allocation may im- 
prove as clinical knowledge improves (e.g., with the publication of  new 
studies on large benefits or adverse effects of treatment) or as clinical expe- 
rience increases (e.g., as cardiologists become more familiar with the types 
of patients likely to benefit from intensive procedures). 
Unfortunately, obtaining longitudinal information on appropriateness 
of treatment is very difficult. Though many studies report information on 
the clinical characteristics of enrolled patients, they generally do not report 
statistics on treatment rates in particular clinical subgroups of patients at 
the level  of detail required for appropriateness judgments. Even if  they 
did, the sample sizes involved would likely be too small to reach definitive 
conclusions about changes in appropriateness over time. Finally, studies 
designed to examine appropriateness of care at a point in time often clas- 
sify a large share of patients into a “possibly appropriate” category, where 
benefits of treatment are uncertain, and judgments about appropriateness 
may differ (Ayanian et al. 1998). For all of these reasons, the clinical-trial 
literature and our analysis necessarily focus on average effects of treatment 
across broad groups of patients. Though we must treat it as a residual, we 
suspect that improvement in appropriateness of  care also contributed to 
the observed improvements in outcomes. 
9.3.3  Prehospital Treatment Changes 
As we noted above, much of the decline in out-of-hospital deaths from 
AM1 (and IHD-associated ventricular arrhythmias) appears to be the re- 
sult of a decline in the total incidence of AM1 and cardiac-arrest events. 
In this section, we  review evidence on the prehospital treatment of AM1 
and AMI- and IHD-related cardiac arrest. If more AM1 patients survive 
to hospitalization as a result of improved prehospital treatment, then the 
share of AM1 hospitalizations among total AMIs will increase. The sub- 
stantial decline in out-of-hospital IHD death rates relative to the AM1 
hospitalization rate suggests that this is indeed the case. To the extent that 
these additional hospitalized patients have more or less severe AMIs than 
average, these changes may have implications for apparent survival rates 
after hospitalization for AMI. 
Advanced Cardiovascular Life Support (ACLS)  Availability 
Goldman and Cook (1984) estimated that ACLS accounted for 8.4 per- 
cent of the reduction in IHD mortality between 1968 and 1976. They esti- 
mated that if  ACLS had  been widely available, 36,000 deaths per  year 386  Paul Heidenreich and Mark McClellan 
during this period could have been prevented. However, only 600 lives per 
year were  actually saved, because most people had access to  basic life 
support only. The availability of ACLS may have increased over the last 
twenty years due to increased use of ambulances by  the public and the 
diffusion of the 911 system. It is now estimated that over 90 percent  of 
the U.S. population has emergency medical services available within ten 
minutes (Cummins 1993), and that most have access to basic 91 1 services 
(Hunt et al. 1989). 
Although improved access to defibrillation has probably improved out- 
comes of cardiac arrest victims, it is unclear if the improved access to care 
has had an effect on mortality from AM1 for patients without a cardiac 
arrest (tables 9.6 and 9.7). There is little evidence that rates of ambulance 
use by AM1 patients have increased. According to a review by  Ho et al. 
(1989), 30 to 50 percent of MI patients used an ambulance in 1975, com- 
pared with 42 percent for the Minneapolis metropolitan area in 1990. Even 
though ACLS availability has increased substantially, its actual emergent 
use  for AM1 patients has probably increased  only modestly. Thus,  the 
share of mortality improvement for hospitalized AM1 patients explained 
by changes in ACLS availability up to 1995 is probably small. 
Cardiac Arrest Treatments 
Several studies have documented improvement in survival from out-of- 
hospital cardiac arrest following implementation  of  systems using para- 
medics or defibrillation-trained  emergency medical technicians  (EMTs) 
(Vukov, White, and Bachman 1988; Weaver et al. 1986). In Seattle, the per- 
cent of patients discharged alive increased from 10 percent in 1971 to 25 
percent in 1973 following the establishment of a comprehensive program 
to improve access to advanced cardiac life support including defibrilla- 
tion (Weaver et al. 1986). Little improvement occurred during the subse- 
quent ten years (26 percent survival to discharge in 1983) despite imple- 
mentation of new  treatments such as automated defibrillators (Cummins 
et al. 1987), and dispatcher-assisted cardiopulmonary resuscitation (CPR) 
(Eisenberg et al. 1985). A  similar improvement in survival (2.5 percent 
to 12 percent) for cardiac arrest patients with ventricular fibrillation was 
observed following the use of defibrillators by EMTs (Vukov, White, and 
Bachman  1988). The focus of  cardiac arrest treatment has been on de- 
fibrillation because  50  to 80 percent  (Eisenberg et  al.  1990; American 
Heart Association  1992) of patients are found in this rhythm (Cummins 
1993). 
A few additional treatments have been noted to improve survival in car- 
diac arrest. Bystander CPR, when performed correctly, has been associ- 
ated with an increased probability of the patient’s being in ventricular fib- 
rillation when emergency personnel arrive, and with an improved outcome 
(4.6 percent survival with effective CPR versus 1.4 percent with ineffective Table 9.6  Trends in Prehospital Treatment for Myocardial Infarction 
1973-77  1978-82  1983-87  1988-92  1993-95  Source 
Patient-Related 
Time to call 91 1 (hours) 
Use of ambulance (YO) 
Time to hospitalization (hours) 
mean (median) 
Hospital 
Arrival-lytics (minutes) mean 
(median) 
Arrival-lytics CCU (minutes) 
Arrival-lytics ER (minutes) 
33-50 
> 4 in 
40-50% 
2-2.6  2.1  > 6 in 40%  Ho et al. (1989); Sharkey et al. (1989) 
50  44  42  Ho et al. (1989); Sharkey et al. (1989); 
Kereiakes et al. (1990) 
Investigators (1997); Ho et al. (1989); 
Maynard et al. (1995) 
4.1 (2.0)  4.6 (2.0)  (2.7)  Yarzebski et al. (1994a); GUSTO 111 
90  99 (57)  Sharkey et al. (1989) 
102  73 
67  47 
Sharkey et al. (1989); Maynard et al. (1995) 
Sharkey et al. (1989); Maynard et al. (1995) 388  Paul Heidenreich and Mark McClellan 
Table 9.7  Effects of Different Prehospital Technologies for Acute Myocardial Infarction and 
Cardiac Arrest 
Estimate: 
EKects  Absolute Benefit  SourceIComment 
Use of paramedics or 
Effective bystander CPR (5) 
15  Survival increased from IO’X to 25% (Weaver 
4.6% survival with effective CPR vs.  1.4”/0 
with ineffective CPR (Gallagher, Lom- 
bardi, and Gennis 199) 
No effect on time delay or use of ambulance 
(Ho et al. 1989; Blohm et al. 1996) 
EMT-Dd (nh)  et al. 1986) 
3.2 
Media campaign to increase 
use of EMSb  (I%) 
Prehospital thrombolysis (%)  2.2  (Weaver 1995) 
Prehospital ECG (Y”) 
Lytics in  1 hour ((%I)  6.9  (Boersma et al. 1996) 
Lytics in 6 hours (%)  2.6  (Boersma et al. 1996) 
Paramedics vs. EMT  (I%) 
0 
4.3  Decreased time to lytics by 40 mins (Barbash 
et al. 1990; Canto et al. 1996) 
8  24% paramedics vs. 16% EMTs (all benefit in 
hypotensive patients) (Pressley et al. 1988) 
“EMT-D: emergency medical technicians with defibrillation training 
hEMS:  emergency medical services. 
CPR) (Gallagher, Lombardi, and Gennis 1995). In contrast, other treat- 
ments such as the use of high-dose epinephrine (Callaham et al. 1992), 
transcutaneous pacing (Cummins et al.  1993), and active compression- 
decompression CPR (Schwab et al. 1995)  have not been shown to improve 
survival to hospital discharge. 
It is unclear if the 91 1 system has an effect on acute MI mortality apart 
from  improved  access  to defibrillation.  A  study  of  trauma patients  in 
North Carolina found no improvement in trauma death rates following 
institution of the system (Patsey et al. 1992). A comparison with counties 
that lacked 91 1 also did not  show a benefit. Although  similar data for 
AM1 patients are lacking, the time from symptoms to hospitalization, an 
important determinant for benefit from thrombolysis,  has not  changed 
dramatically (table 9.6). Taken together, these improvements in prehospi- 
tal  care for AM1 and arrest appear to  account for a small part of the 
overall IHD and AM1 mortality reduction. 
Overall Changes in Survival to Hospitalization of  AM1  Patients 
The changes in out-of-hospital treatment probably had a relatively mod- 
est effect on the higher rates of survival to hospitalization of AM1 patients. 
In this section, we compare this evidence on prehospital treatment changes 
to the  overall changes in  survival  of out-of-hospital arrests and severe 
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Different studies have reported widely divergent survival rates for out- 
of-hospital events, and Becker, Smith, and Rhodes (1993) demonstrated a 
striking  inverse relationship  between  reported  incidence  and  survival. 
Studies with an incidence of 120 per 100,000 had survival rates of 2 to 3 
percent.  Other studies with higher survival rates  (5 to  18 percent) had 
much lower incidence rates (40 per  100,000) (Cummins et al. 1985). Al- 
though these differences may be related to differences in patient popula- 
tions, the threefold variation in reported incidence among studies strongly 
suggests that different inclusion criteria were used to identify the popula- 
tion receiving prehospital care. After adjustment for differences in inci- 
dence rates, there was no clear trend in survival rates over time from the 
data reported between 1970 and 1990. This observation is limited by publi- 
cation bias: Areas with advanced prehospital care programs may be more 
likely to report data. If we assume that lower incidence rates in some areas 
result from more patients receiving no prehospital care before death, we 
can assume that  the rate of out-of-hospital events is  approximately  150 
cases of arrest and AMI-related cardiogenic shock per 100,000. The sur- 
vival rate for out-of-hospital events (using an incidence of 150 arrests per 
100,000) is 1 to 5 percent. As our review of changes in prehospital technol- 
ogies suggested, the actual improvements in prehospital treatment appear 
to account for only a modest  increase in  the number  of AM1 patients 
reaching the hospital alive. 
Though they  may have modestly improved population AM1 survival 
rates, these prehospital treatment changes did not necessarily improve the 
thirty-day survival rate for hospitalized AM1 patients. The “marginal” pa- 
tients saved in the field may be relatively ill when reaching the hospital. In 
support of  this hypothesis are data from Minnesota, which demonstrate 
an increase in the death rate from ischemic heart disease in the emergency 
room from  1970 to 1978 (Gillum et al. 1983). Partly for this reason, we 
examine trends in the characteristics of hospitalized AM1 patients to as- 
sess their contribution to the apparent trends in AM1 survival rates. 
9.3.4  Changes in Characteristics and 
Reporting of AM1 Hospitalizations 
Outcomes of hospitalized  AM1 patients will change over time in  the 
absence of changes in effective treatment if the characteristics of the AM1 
populations change. Changes in survival to hospitalization are one source 
of changes in patient characteristics, but changes in the health risks of pa- 
tients hospitalized with AMI, diagnostic accuracy, and other factors may 
also have contributed. In this section, we review the evidence on whether 
changes in the nature or severity of hospitalized AMIs have affected out- 
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Presenting Characteristics 
Data on all hospitalized AM1 patients from NHDS show some changes 
in AM1 patient  demographics (table 9.8).1° The average age of the acute 
MI patient has increased from sixty-four to sixty-nine years. The propor- 
tion of MI patients that are female has increased from 33 percent in 1975 
to over 40 percent in the 1990s (Goldberg et al. 1986; Chandra et al. 1997). 
Data from Minnesota demonstrate some reduction in the risk-factor pro- 
file  (cigarette  smoking,  hypercholesterolemia,  systolic  blood  pressure) 
from 1985 to 1990, which might lead to better outcomes. The precise ex- 
tent to which these modest changes in risk factors have affected thirty-day 
AM1 mortality  is unclear,  but the impact  has probably  not  been  sub- 
stantial. 
Infarct Type, Locution, and Severity 
According  to data from the Worcester  Heart Attack  Study, between 
1975 and 198  1 the rate of non-Q-wave MI  increased relative to the Q-wave 
MI rate (Goldberg et al.  1986). A likely reason  for this  increase is  the 
improved detection of MI with creatine kinase (CK) cardiac enzymes. In 
1975 medium serum creatine kinase (CK-MB) fractions and other chemis- 
try tests for AM1 confirmation were used  in 5 percent of infarcts, com- 
pared to 58 percent in 1981 (Goldberg et al. 1986) and in over 90 percent 
of cases by the late 1980s. This increased use of cardiac enzymes may in 
part explain the observed increase in acute MI discharges at a time when 
overall mortality  from MI was decreasing. In addition, improved initial 
detection and treatment of AM1 may decrease the myocardial damage, re- 
sulting in a greater share of non-Q-wave infarcts. Non-Q-wave infarctions 
have better short-term mortality  than Q-wave infarcts, although this dif- 
ference does not appear to persist for long-term outcomes (Goldberg et al. 
1987a; Behar et al. 1996). If we  assume that two-thirds of the decline in 
Q-wave MI is due to improved treatment, then the remaining decline due 
to improved detection would explain 27 percent of the overall decline in 
thirty-day mortality. 
Anterior location of the infarct appears to have dropped, perhaps also 
because of increased diagnosis of nonanterior infarcts, from 58 percent in 
1975 to 43 percent in the early 1990s (Goldberg et al. 1986; Chandra et al. 
1997). However, recent data from the GUSTO trials (GUSTO 111 Investi- 
gators 1997) suggest that the proportion of patients with anterior infarcts 
may have increased somewhat since 1993 (40.9 percent to 47.5 percent in 
1996). Past studies have shown that mortality from an anterior MI is 50 
10. Because we have used age-specific incidence rates to calculate the overall death rate, 
the impact of changing distributions of ages does not account for the unexplained reduction 
in our reported case-fatality rates. However, these demographic changes may be associated 
with other changes in case characteristics. Table 9.8  Trends in Patient Characteristics 
1973-77  1978-82  1983-87  1988-92  1993-95  Source 
Age (years)  64.1  65.5  67.5  68.4  69.1  NHDS 
Female gender ('YO)  33  37  40  40  40  NHDS 
Anterior or lateral  58  58  44  46  GUSTO 111 Investigators (1997); Goldberg et al. (1986); 
Q-wave MI  72  57  48  32  Goldberg et al. (1986); Mickelson, Blum, and Geraci (1997); 
Shock  7.6  7.3  7.6  9.  I  2.9  Goldberg et al. (1991); Goldberg et al. (1986); Canto et al. 
location  Chandra et al. (1997); Mickelson, Blum, and Geraci (1997) 
McGovern et al. (1997) 
( 1996) 
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Table 9.9  Infarct Characteristics  and Mortality 
Effect Size  Odds Ratio 
Age  I .05 
Male  ns. 
Anterior location  1.52 
Q-wave MI  2.32 
Shock (Killip IV)  7.89 
Source: Canto et al. (1996). 
No/e: All p < 0.001; n.s. = not significant. 
percent greater  regardless  of  Q-wave or non  Q-wave type, and anterior 
MIS have higher mortality  than inferior infarcts even after adjusting for 
size of infarction (table 9.9) (Behar et al. 1993, 1996; Haim et al. 1997; Kor- 
nowski et al. 1997). If we assume that the relative death rates for anterior 
and inferior infarcts did not change, then the change in distribution of MI 
(more inferior) would explain  12 percent of the decrease in case-fatality 
rates. 
A final source of evidence on changes in severity of infarcts is the share 
of patients who experience symptoms of cardiogenic shock. There is some 
evidence that average AM1 severity given distribution increased through 
the late 1980s. According to the Worcester series, the incidence of shock 
increased slightly, from 7.6 percent in 1975 to 9.1 percent in 1988 (Gold- 
berg et al. 1991). However, data from NRMI suggest that the prevalence 
of shock in more recent years is less than 5 percent, and shows no clear 
trend. If  the NRMI data are correct,  then decreasing  MI severity over 
the entire time period  can explain up to 30 percent  of the reduction  in 
AM1 mortality. 
Available data on patient characteristics and infarct severity do not per- 
mit definitive conclusions, but the bulk  of the evidence suggests that the 
changes in the nature of AMIs in hospitalized patients accounts for a sig- 
nificant  part of the observed  improvements in outcomes, especially  be- 
tween 1975 and 1985. Taken together, the changes in infarct type, severity, 
and location would plausibly explain  around one-third  of the thirty-day 
mortality improvement for AM1 between  1975 and 1995. 
Changes in Reporting 
Changes in coding practices and consequent increases in noncardiovas- 
cular death rates may explain some of the decline in IHD death rates (Pan- 
kow et al. 1994). A mathematical model of the decline in ischemic heart 
disease mortality estimated that 5 to 10 percent of the decline in mortality 
from  1970 to  1989 is due to definitional changes in the cause of death 
(Gilbertson et al. 1992). However, this model applied to all AM1 deaths, 
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sify precisely. Studies based on clinical audits of Medicare discharge re- 
cords suggest that the discharge diagnosis of AM1 has a positive predictive 
value of 95 percent or higher for true AMIs (Green and Wintfeld 1993). 
This high level of accuracy for AM1 does not appear to have changed 
much over time. Thus, it appears unlikely that changes in reporting prac- 
tices have had a substantial impact on observed AM1 trends. 
9.3.5  Changes in Postacute Care and Long-Term Outcomes 
Our results suggest that most of the substantial improvement in thirty- 
day AM1 mortality over the past twenty years can reasonably be attributed 
to changes in medical treatments. An important question is the extent to 
which the thirty-day mortality improvements translate into long-term re- 
ductions in mortality for AM1 patients. Medicare beneficiaries hospital- 
ized with AM1 between 1984 and 1994 had larger mortality reductions up 
to three to five years after AM1 than they did at thirty days (McClellan 
and Noguchi 1988). However, variations in hospital treatment explained a 
significantly smaller share of one-year than thirty-day mortality variations 
for these patients (McClellan and Staiger 1999), suggesting that the long- 
term mortality improvements required the interaction of changes in hospi- 
tal treatment with changes in subsequent treatment and behavior that led 
to secondary prevention.  Unfortunately, less quantitative evidence exists 
on the effectiveness of postacute treatments, and especially on trends in 
their use  in  post-AM1 patients.  We  review  the available evidence here, 
which permits only qualitative estimates of the sources of improvements 
in long-term outcomes after AMI. 
Reductions in mortality with beta blockers (odds ratio 0.81, 95 percent 
confidence interval  [CI] 0.73-0.89),  antiplatelet agents (0.90, 0.82-1 .O), 
cholesterol lowering agents (0.86, 0.79-0.94),  anticoagulants (0.78, 0.67- 
0.90) and rehabilitation  programs (0.80, 0.65-0.95)  have been  demon- 
strated  by  multiple  randomized  trials.  The  benefit of  calcium  channel 
blockers is unclear (odds ratio 1.01, 95 percent CI 0.90-1.12),  while class 
1  antiarrhythmic agents appear to be harmful (1.28, 1.02-1.61)  (see Lau 
et al. 1992 for a summary of these trials). 
Changes in the use of these and other postacute treatments are less clear 
than the evidence on their likely effectiveness. A survey of internists by 
Hlatky  et al. (1988) found increased long-term beta blockade,  from  35 
percent in 1979 to 82 percent in 1987, for a patient with an uncomplicated 
MI. Actual use is likely to be considerably lower because many patients 
have complicating factors that make them less than ideal candidates, and 
because  of compliance problems.  Data from outside the United  States 
show an increase in postdischarge beta blockade use from 30 to 40 percent 
in the early 1980s to over 60 percent in the 1990s (Myers 1985, Thompson 
et al.  1992). Our analysis of  data from the Cooperative Cardiovascular 
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admission  to 46 percent of  Medicare patients,  only 27 percent  received 
them at discharge. 
A  substantial  increase  in  long-term  aspirin use was  also  reported  in 
Hlatky et al.3 (1988) physician survey, from 35 percent in 1979 to 82 per- 
cent in 1987. Data from Medicare beneficiaries in 1992-93  found that 76 
percent of patients without a contraindication received aspirin (Krumholz 
et al. 1996). Non-US. data also suggest that postdischarge aspirin use has 
increased significantly worldwide, from 33 percent in 1985 to over 80 per- 
cent in the early 1990s (Thompson et al. 1992; Smith and Channer 1995). 
The increase in long-term aspirin use may be an important contributor to 
long-term outcome improvements. 
Data from Medicare (CCP) in 1994 reveal that 26 percent  of patients 
received calcium channel blockers,  24 percent  received  ACE inhibitors, 
and 11 percent received warfarin at discharge. NRMI results also show 
that use of ACE inhibitors at discharge appears to be increasing slowly 
but steadily in the United States, to around one-fourth  of AM1 patients 
by  1995 (McClellan et al., in press). International data document increas- 
ing use of calcium channel blockers from their first use in the early 1980s 
to a peak in the mid- to late 1980s of 40 to 50 percent, followed by a sub- 
sequent decline (Smith and Channer 1995; Zuanetti et al. 1996; Heller et 
al. 1992). Long-term use of nitrates and anticoagulants show no dramatic 
trends following AMI, at least over the past decade (Myers 1985; Thomp- 
son et al. 1992; Smith and Channer 1995; Heller et al. 1992). 
In 1990 an estimated  10 to 15 percent of MI survivors participated in a 
supervised  outpatient  cardiac rehabilitation  program (Wittels,  Hay, and 
Gotto 1990; American College of Physicians  1988). This is less than the 
fraction of MI survivors (38 percent) in the GUSTO trial who were en- 
rolled in cardiac rehabilitation programs (Mark et al. 1994). However, the 
GUSTO patients were a select group whose use of rehabilitation services 
may differ from that of the general population. The use of rehabilitation 
appears to be increasing over time, but little quantitative data exist on the 
magnitude of these trends. 
Post-AM1  catheterization  and  revascularization  procedures,  particu- 
larly angioplasty, became much more widespread between  1975 and 1995. 
Clinical trials have only documented a clear long-term mortality  benefit 
from revascularization for a small fraction of IHD patients (Yusuf et al. 
1994), and even in these cases the mortality differences were not evident 
until six months following surgery. Several recent trials have found no mor- 
tality benefit and possibly increased mortality risk with routine catheter- 
ization after AM1 (Boden et al. 1998). Thus the limited available clinical 
trial evidence suggests that the additional procedures have had a modest 
impact on overall mortality  trends.  International  comparisons of trends 
in long-term outcomes for AM1 patients find results consistent with this 
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procedure use have had near-identical trends in mortality improvements 
(McClellan  et al., in press). Some observational evidence suggests that 
more intensive procedure use may lead to improved quality of life (Rou- 
leau et al. 1993). But few studies have evaluated trends in quality of life for 
AM1 patients, so that conclusions about the contribution of more intensive 
procedures to long-term quality of life would be highly speculative. 
Risk factors have also improved over the last several years for the gen- 
eral population, and improvements are likely to be similar if not greater 
for patients following MI. Smoking rates have dropped steadily between 
1975 and  1995. Cholesterol levels dropped between  1960 and the mid- 
1980s, largely due to changes in diet (Goldman and Cook 1984), and they 
have dropped more substantially since the late 1980s, probably as a result 
of increased use of cholesterol lowering agents (statins). Data from the 
National Health and Nutrition Examination Survey (NHANES) indicate 
a yearly drop in total and LDL (low-density lipoprotein) cholesterol of 
0.25 to 0.6 percent.  Hypertension is also better  controlled, particularly 
systolic hypertension in the elderly, again probably as a result of both be- 
havioral changes (especially before 1980) and new drug treatments. Dia- 
stolic blood pressure has also decreased approximately 0.15 to 0.2 percent 
per  year according to data from  Minnesota  (McGovern, Burke, et  al. 
1992). Obesity rates, in contrast, have increased from the mid-1980s on- 
ward. Data from NHANES suggest a 0.25 to 0.4 percent increase in body 
mass index per year. Taken together, these reductions in risk factors may 
be important contributors to the long-term sustainability of the short-term 
outcome improvements that we have described in detail. Both behavioral 
changes, especially in the early period  of  our study, and more effective 
drug therapy in more recent years have mediated these effects. 
These results on long-term outcome improvements after AM1 yield sev- 
eral qualitative conclusions. First, the substantial improvements in short- 
term mortality appear to translate into long-term mortality improvements. 
Second, changes  in  both  postacute  treatment-increased  use  of  drugs 
including aspirin, beta blockers, statins, and antihypertensive drugs, and 
(perhaps  to  a  lesser  extent)  increased  use  of  revascularization  proce- 
dures-as  well  as changes in risky behaviors have contributed to these 
improvements. Though  quantitative conclusions  are not  possible  using 
published data on effectiveness and treatment trends, it is likely that be- 
havioral changes were relatively important up to the early 1980s, and that 
changes in medical treatments have accounted for the bulk of the improve- 
ments since. These qualitative conclusions about long-term mortality are 
generally consistent with our findings on the sources of acute mortality 
improvements, as well as with the conclusions of more general studies of 
IHD mortality trends (Goidman and Cook  1984; Weinstein et al. 1987; 
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9.3.6  Cost-Effectiveness of Technological Change for AM1 Care 
Our results indicate that changes in medical technology have accounted 
for the bulk of improvements  in acute AM1 mortality, and probably  of 
long-term AM1 mortality, over the past two decades. With the cost of AM1 
treatment increasing substantially over the same period (McClellan and 
Noguchi 1988; Cutler et al. 1998), an important policy question is whether 
these changes have been cost-effective. A comprehensive approach to this 
question would require a detailed analysis of the cost of each of the tech- 
nologies that we have studied, including their downstream impact on other 
expenditures. Such an analysis is beyond the scope of this paper. Here, we 
review some of the overall changes in thirty-day and longer-term expen- 
ditures  on  AM1  patients,  and  discuss  their  implications  for  cost- 
effectiveness. 
Resource Use, Costs, and Expenditures 
The length of stay for patients hospitalized with myocardial infarction 
has  declined  consistently  since  1975 (table 9.10). Data from discharge 
surveys and GUSTO 1-111 (GUSTO 111 Investigators 1997) show a drop 
from fifteen days in 1976 to seven or fewer in 1995. Medicare data on to- 
tal length of stay for the thirty days and year after AM1 show a similar, 
though slightly less dramatic, decline in total hospital days over the past 
decade. The decline is slightly less dramatic due to the increasing use of 
readmissions and transfers documented in table 9. I. 
Despite the reduction in use of hospital days, total resource use in AM1 
care has increased  substantially over  the past  two decades.  Because  of 
increasing use of intensive cardiac procedures, thrombolytics, other drugs, 
and intensive procedures during the initial AM1 episode of care, the cost 
of each hospital day has grown more than enough to offset the reduced 
length  of  stay. Hospital list charges for AM1 care have increased  enor- 
mously: $4,752 in 1975 in Boston (Cretin 1977), $15,900 in San Francisco 
in 1982 (Sawitz et al. 1988), and $30,000 in Midwestern community hospi- 
tals (Leimbach et al. 1988) to $39,000 in Ann Arbor  (Chapekis,  Burek, 
and Topol  1989) in  1987. List charges are increasingly  misleading mea- 
sures of resource use, particularly  since the late  1980s, because of  man- 
aged-care contracting and government price regulation. However, studies 
based on estimated resource costs and actual reimbursements for medical 
services have qualitatively similar results. Studies from Boston  hospitals 
using detailed cost per charge ratios to estimate costs have found an in- 
crease in mean costs from $10,638 in 1986 (Tosteson et al. 1996) to $15,073 
in  1992 (Di et al. 1996). These trends are reflected in provider payments 
for AM1 care: The thirty-day DRG payments for the Medicare population 
have increased steadily since 1985, and their growth may have accelerated 
since 1992 (McClellan and Noguchi 1988). Table 9.10  Trends in Resource Utilization and Cost 
Length of stay (days) 
ICU length of stay (days) 
Hospital charges I  year (1995$) 
Hospital costs 1 year (using cost- 
charge ratio) (1995$) 
Hospital costs 30-day (using 
Medicare reimbursements) (1995$) 
Hospital costs 1 year (using Medicare 
reimbursements) (1995$) 
1973-77  1978-82  1983-87 
16.5  14.0  10.5 
5.8 




1988-92  1993-95  Source 
8.3  7.1  HCIA Inc. 
4  3.5  Leimbach et al. 1988; Mark et al. 1995; 
Reeder et al. 1994 
Burek, and Topol 1989 
Cretin 1977; Sawitz et al. 1988; Chapekis, 
Tosteson et al. 1996; Paul et al. 1995  15,000 
9,500  12,300  Medicare data from 1985, 1990, 1994 
14,200  18,200  Medicare data from 1985, 1990, 1994 398  Paul Heidenreich and Mark McClellan 
Cost-  Effectiveness 
Using Medicare data on thirty-day expenditures for treatment, we  esti- 
mated  the  aggregate  cost-effectiveness of  interventions  for  MI  by  de- 
termining the total cost of care and the expected quality-adjusted life years 
gained from all acute MI treatments. If we  extend the 5.0 percent yearly 
real increase in total thirty-day medical expenditures observed between 
1985 and 1995 (McClellan et al. in press) back to 1975, we would have ob- 
served a total increase in medical expenditures of $8,500 over the last twenty 
years. Because a greater percentage of patients are surviving their AMI, 
their long-term medical and nonmedical costs also rise. If we assume that 
the quality-of-life adjustment for surviving post-AM1 has remained con- 
stant at 0.88 (Tsevat et al. 1993), then the discounted (3 percent per year) 
quality-adjusted life years (QALYs) over five years are forty QALYs per 
100 patients treated (table 9.11). If quality of life of AM1 survivors has 
actually improved over time, for example through better symptomatic re- 
lief from medications and revascularization, the QALY gains would be 
even larger. 
Our estimates indicate that changes in AM1 technology accounted for 
over 60 percent of the increase in QALYs. If we  further assume that the 
changes in technology were responsible for all of the expenditure growth 
(Cutler and McClellan  1998), then the marginal cost-effectiveness for all 
Table 9.11  Cost-Effectiveness Calculations 
5-Year Survival  10-Year Survival  15-Year Survival 
Increase in MI cost (1995-75)  per 100  8,500  8,500  8.500 
patients (S) 
per 100 patients 
Increase in MI survivors (1995-75)  8.3  8.3  8.3 
Quality adjustment for living post-MI  0.88  0.88  0.88 
Increase in long-term health costs  181,000  337,000  472,000 
due to MI survivors per 100 
patients (assumes $4,00O/year/ 
survivor) ($) 
patients ($) 
(QALYs) per 100 patients 
Increase in total costs per 100  1,029,000  1,185,000  I .3 19,000 
Increase in quality-adjusted life years  40  77  108 
. costs/. QALYs ($)  26,000  15,000  12,000 
Adjusted . costs/. QALYs ($)  42,000  25,000  20.000 
QALYs due to interventions (QALYs  25  48  67 
X  0.62) per 100 patients” 
Adjusted . costs/. Life years ($)  35,000  20,000  15,000 
Note: All long-term costs and utilities are discounted at 3 percent per year (1995 dollars). 
“Uses  estimate of reduction in mortality from medical technologies from table 9.4. Trends in Heart Attack Treatment and Outcomes  399 
treatments combined is $42,000 per QALY if  patients survive five years 
post-MI, and $25,000 per QALY if patients survive ten years. Assuming a 
fifteen-year life expectancy following AM1 (Mark et al. 1995), the cost per 
QALY gained is $20,000 and the cost per year of life gained is $16,000. 
These values cluster toward the low end of commonly accepted thresholds 
for cost-effectiveness of $25,000 to $100,000 per year of life saved (Lau- 
pacis et al. 1993). 
The favorable results on the average value of all the changes in medical 
technology for AM1 care do not imply that all of the many particular 
changes in AM1 treatment have been cost-effective. For example, greater 
use of catheterization and revascularization can explain almost all of the 
growth in hospital payments for Medicare beneficiaries with AM1 over the 
past decade (Cutler and McClellan 1998). But the evidence reviewed here 
suggests that these procedures account for only a small part of the short- 
and long-term mortality improvements, and these particular  treatments 
may not have favorable cost-effectiveness ratios in themselves. In contrast, 
the cost-effectiveness of aspirin is extremely favorable. 
9.4  Discussion 
The treatment of AM1 has changed enormously during the past twenty 
years. The use of interventions that have been shown to be effective in 
randomized clinical trials (aspirin, beta blockers, primary PTCA, throm- 
bolytics) have increased, while the use of possibly harmful technologies 
(lidocaine, calcium channel blockers) has declined. Many other technolo- 
gies with uncertain effectiveness have also become more widely used. 
Recently, Hunink et al. (1997) reported the results of a Markov model 
of coronary heart disease to evaluate the importance of  such changes in 
care for understanding the decline in IHD deaths from 1980 to 1990 (see 
also Weinstein et al. 1987). The study estimated that improvements in the 
thirty-day mortality rate for acute MI explained 15 percent (19,000 deaths) 
of the drop during this period. The coronary heart disease policy model 
did not incorporate individual treatment for acute myocardial infarction 
such as thrombolytic therapy or primary angioplasty, thus, the particular 
contributions of these interventions could not be determined. 
Our goal was to understand the extent to which specific changes in AM1 
treatment  and other factors could explain outcome trends for AM1 pa- 
tients. We  developed quantitative estimates of changes in  overall AM1 
mortality, including both hospitalized patients and those who die before 
hospitalization.  Though we  explored the likely consequences of  changes 
in prehospital treatment and postacute AM1 care, published studies were 
adequate to provide quantitative estimates only of  the consequences of 
changes in acute mortality for hospitalized AM1 patients. For this impor- 
tant group of AM1 patients, we  quantified the likely effects of all of  the 400  Paul Heidenreich and Mark McClellan 
significant medical and nonmedical factors that might explain the decline. 
We  found that changes in medical technology explain around two-thirds 
of the decline in thirty-day mortality  rates. A small part of the residual 
decline in thirty-day mortality  rates may be due to other treatments for 
which  quantitative evidence  on effectiveness and use was not available. 
But changes in AM1 patient characteristics  are probably  responsible  for 
the bulk of the residual one-third reduction. Among the nontreatment fac- 
tors,  improvements  in  diagnosis  appear to have  led  to improved  case- 
fatality rates as more patients with small, mild infarcts are being identified. 
However, improved early diagnosis, leading to more rapid use of effective 
technologies and thus more  “incomplete”  non-Q-wave AMIs, may  also 
have contributed to this effect. 
Technologies differed substantially in their impact on the reduction  in 
thirty-day  mortality  rates. The use of beta blockade  and anticoagulants 
increased only slightly and minimally contributed to the decline in case- 
fatality rates. Thrombolysis and primary PTCA have also become much 
more  widespread  since  1985, contributing significantly  to the mortality 
improvement over the past decade. The greatest contributor to the decline 
in case-fatality rates was the diffusion of aspirin. Clinical trials have docu- 
mented a substantial effect of aspirin on mortality, even in the postthrom- 
bolytic  era.  More  importantly,  aspirin  use  increased  enormously,  from 
around  15 percent  in  1975 to 75 percent  in the early  1990s. The use of 
aspirin for secondary prevention of MI has also increased in the United 
States. Thus aspirin appears to be the most important factor in explaining 
the cost-effectiveness of technological change in AM1 care for both short- 
and long-term mortality improvements. Other changes in technology have 
probably been less cost-effective, and may not have been worth their addi- 
tional resource costs. 
To our knowledge, this is the most detailed quantitative analysis of the 
contribution of specific changes in medical technology to changes in popu- 
lation outcomes. Our findings suggest that the medical treatment changes 
can explain over 60 percent of the observed improvements in mortality for 
hospitalized  AM1 patients,  and have  been  particularly  important since 
1985. The remainder of the mortality improvement can probably be attrib- 
uted to reductions in the average severity of hospitalized AM1 patients, in 
association with improvements in techniques for diagnosing mild non-Q- 
wave  MIS. Important as the changes in acute treatment collectively ap- 
peared to be, we found that they accounted for only a minority-less  than 
one-fourth-of  the overall decline in population AM1 mortality rates dur- 
ing the 1975-95 period. Most of the observed reduction in AM1 mortality 
was associated with a large decline in the number of serious AM1 events 
resulting in either prehospital deaths or hospitalization.  Further  studies 
could extend our detailed  decomposition  techniques  to explaining “pri- 
mary prevention” trends, building on the general descriptive work of Hun- Trends in Heart Attack Treatment and Outcomes  401 
ink et al. and others. Fewer quantitative clinical studies have examined 
the use of preventive medical treatments and their individual effects on 
outcomes, so a quantitative analysis of the contribution of particular pre- 
ventive treatments to the reductions in AM1 event rates that we estimate 
may be difficult. The same problem applies to understanding the specific 
factors responsible for improvements in long-term AM1 outcomes. None- 
theless, a careful review of the changes in treatments and outcomes for pri- 
mary and secondary prevention could provide important insights into why 
these outcomes have changed and the cost-effectiveness of these changes, 
as well as identifying key areas of uncertainty for future clinical studies. 
Our results demonstrate that changes in medical treatment are becom- 
ing more important, and changes in behavior are becoming relatively less 
important, in accounting for the substantial improvements that have oc- 
curred in acute and long-term AM1 outcomes. Steady growth in the use 
of particular technologies suggests that the use of beneficial acute thera- 
pies may become even more widespread over the next several years. To 
explore the consequences of increased use of beneficial therapies, we deter- 
mined the improvement in thirty-day mortality rate that would occur if 
(1) aspirin use increased to 90 percent, (2) beta blockade increased to 80 
percent, and (3) thrombolysis or primary PTCA increased to 50 percent. 
These changes in treatment, which may occur over the next five  to ten 
years if current trends continue, would reduce thirty-day mortality to 15 
percent (14 percent relative decrease, 2.5 percent absolute decrease relative 
to 1995 mortality). Because these therapies are relatively underused in the 
elderly, who still have relatively high mortality rates, even larger reductions 
might be possible. 
Changes in prehospital care also remain a potential source of outcome 
improvements. Treatment of cardiac arrest with early defibrillation has be- 
come more readily available. However, few  studies have  suggested that 
other aspects of prehospital treatments for AM1 have changed substan- 
tially between 1975 and 1995. For example, studies of 1975 and 1990 AM1 
patients found similar rates of ambulance use, and several studies have 
failed to document improvements in death rates for urgent conditions fol- 
lowing activation or enhancement of 91 1 systems. Improving these emer- 
gency responses and reducing time to effective therapy remains a policy 
priority through initiatives such as the National Heart Attack Alert Pro- 
gram and the Cooperative Cardiovascular  Project. Perhaps these initia- 
tives are beginning to pay off:  In the last few years, evidence from particu- 
lar hospitals suggests that time between hospital arrival and the delivery 
of key AM1 treatments (thrombolytics, primary angioplasty) is declining. 
Even though they do not appear to have played a large role in the improve- 
ments between  1975 and 1995, it is possible that changes in prehospital 
care and reductions in time to treatment will also lead to further improve- 
ments in AM1 mortality. 402  Paul Heidenreich and Mark McClellan 
Many unanswered questions about technological change in AM1 care 
remain. The lack of  quantitative evidence on postacute care for AM1 pa- 
tients complicates forecasts of future changes in AM1 patient outcomes. 
The enormous apparent variation in the cost-effectiveness of the various 
changes in AM1 treatment that have occurred suggests there is consider- 
able room for further improvements in the “productivity” of  AM1 care. 
Have any changes in AM1 treatment been clearly cost-ineffective, and why 
did  they  occur? Which economic incentives  encourage  the most rapid 
adoption of  cost-effective innovations in treatment? Have changes in ap- 
propriateness of treatment choices and the expertise of providers been im- 
portant contributors to outcome trends? Our results suggest that further 
integration of studies on treatment effectiveness with descriptive studies 
on trends in actual patient characteristics, treatments, and outcomes holds 
considerable promise for addressing these questions. 
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